BRUZZESI, ELENA
 Distribuzione geografica
Continente #
NA - Nord America 233
EU - Europa 182
AS - Asia 137
AF - Africa 3
SA - Sud America 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 559
Nazione #
US - Stati Uniti d'America 233
CN - Cina 83
IT - Italia 67
SE - Svezia 51
SG - Singapore 40
RU - Federazione Russa 25
FI - Finlandia 22
DE - Germania 11
IN - India 6
PH - Filippine 5
FR - Francia 2
ID - Indonesia 2
NL - Olanda 2
RO - Romania 2
TN - Tunisia 2
AR - Argentina 1
BR - Brasile 1
EC - Ecuador 1
EU - Europa 1
IR - Iran 1
NG - Nigeria 1
Totale 559
Città #
New York 46
Shanghai 37
Ashburn 34
Boardman 26
Singapore 24
Helsinki 19
Milan 13
Seattle 10
Lawrence 9
Moscow 9
Princeton 9
Busto Arsizio 6
Pune 6
Washington 6
Dallas 5
Rome 5
Shenzhen 5
Vittoria 5
Monsummano Terme 4
Padova 4
Quezon City 4
Angera 3
Borås 3
Jiaxing 3
Lappeenranta 3
Amsterdam 2
Beijing 2
Bucharest 2
Clifton 2
Guangzhou 2
Jakarta 2
Los Angeles 2
Paris 2
Segrate 2
Torre Del Greco 2
Verona 2
Abuja 1
Baoding 1
Campodolcino 1
Cesano Maderno 1
Chongqing 1
Falkenstein 1
Frankfurt am Main 1
Kassel 1
Lainate 1
Munich 1
Nanjing 1
Paliano 1
Pescara 1
Pisa 1
Puerto Eldorado 1
Queens 1
Quito 1
San Pablo 1
San Sperate 1
Secaucus 1
Shaoxing 1
Shenyang 1
São Paulo 1
Verdellino 1
Viterbo 1
Xi'an 1
Xiamen 1
Yangzhou 1
Totale 348
Nome #
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 49
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 42
Failure of on-demand pre-exposure prophylaxis: the risk of HIV drug resistance 33
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 28
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 27
Symptoms and signs of conjunctivitis as predictors of disease course in COVID-19 syndrome 24
HIV-DNA undetectability during chronic HIV infection: Frequency and predictive factors 23
Serum IgG1 and IgG4 could contribute to partial control of viral rebound in chronically HIV-1-infected patients 23
Antibiotic appropriateness for Gram-negative bloodstream infections: impact of infectious disease consultation 22
Beyond stigma: Monkeypox infection in a 27-year-old woman 21
Meningococcus B Vaccination Effectiveness Against Neisseria gonorrhoeae Infection in People Living With HIV: A Case-Control Study 21
SARS-CoV-2 IgG/IgM Rapid Test as a Diagnostic Tool in Hospitalized Patients and Healthcare Workers, at a large Teaching Hospital in northern Italy, during the 2020 COVID-19 Pandemic 20
Prior Neisseria meningitidis (Nm) proctitis does not prevent Neisseria gonorrhoeae (Ng) proctitis among men who have sex with men (MSM) 19
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice 18
Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infection 18
Characteristics of HIV pre-exposure prophylaxis users at first PrEP counselling visit: the CSL-PrEP cohort 18
Monkeypox infection in a hemopoietic stem cell and heart transplant recipient 17
Human Monkeypox Experience in a Tertiary Level Hospital in Milan, Italy, between May and October 2022: Epidemiological Features and Clinical Characteristics 16
Monkeypox infection among men who have sex with men: PCR testing on seminal fluids 15
Proctitis and prostatitis by Neisseria meningitidis among MSM: A case series 15
Antibiotic resistance among sexually transmitted infections: perspectives from clinical practice 15
Monkeypox and pan-resistant Campylobacter spp infection in Entamoeba histolytica and Chlamydia trachomatis re-infection in a man who have sex with men 15
Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study 15
Real-life use of cidofovir for the treatment of severe monkeypox cases 14
Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case-Control Study 13
Mpox Outbreak 2022: A Comparative Analysis of the Characteristics of Individuals Receiving MVA-BN Vaccination and People Diagnosed with Mpox Infection in Milan, Italy 13
Viral Hepatitis and Human Papillomavirus Vaccination during HIV Pre-Exposure Prophylaxis: Factors Associated with Missed Vaccination 12
Association of high-risk sexual behaviours with sexually transmitted infections among men who have sex with men living with HIV 11
Sexually Transmitted Enteric Infections in Men Who Have Sex With Men Living With HIV Over 8 Years of Follow-up 11
Multidrug-resistant Mycoplasma genitalium urethritis: successful eradication with sequential therapy 10
Isolated monkeypox proctitis among men who have sex with men 10
HIV-NAAT use for early detection of HIV infection among high-risk men who have sex with men in Italy 10
Prevalence and Risk Factors of Anal HPV Infection in MSM Living With HIV: Identifying the Target Groups to Prioritize for Immunization 9
HIV viral load monitoring during monkeypox virus infection among people with HIV 8
Breakthrough monkeypox infection among individuals previously immunized with smallpox or monkeypox vaccination 8
Rectal Lymphogranuloma venereum among Men who Have Sex with Men: 7 versus 21 Days Doxycycline Effectiveness 3
Monkeypox Virus Neutralizing Antibodies at Six Months from Mpox Infection: Virologic Factors Associated with Poor Immunologic Response 2
Totale 648
Categoria #
all - tutte 7.306
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.306


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202110 0 0 0 0 0 7 0 1 1 0 1 0
2021/202237 0 0 0 3 0 6 1 7 5 10 2 3
2022/2023124 27 15 4 3 8 8 31 18 3 3 3 1
2023/2024337 7 13 71 27 38 83 3 37 1 4 7 46
2024/2025140 44 12 32 22 30 0 0 0 0 0 0 0
Totale 648